These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 16189129

  • 1. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
    Boffito M, Pozniak A, Kearney BP, Higgs C, Mathias A, Zhong L, Shah J.
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4386-9. PubMed ID: 16189129
    [Abstract] [Full Text] [Related]

  • 2. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
    Kruse G, Esser S, Stocker H, Breske A, Koerber A, Kopperman M, Wiehler H, Ross B, Möcklinghoff C, Hill A, Becker M, Kurowski M.
    Antivir Ther; 2005 Oct; 10(2):349-55. PubMed ID: 15865230
    [Abstract] [Full Text] [Related]

  • 3. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
    Kearney BP, Sayre JR, Flaherty JF, Chen SS, Kaul S, Cheng AK.
    J Clin Pharmacol; 2005 Dec; 45(12):1360-7. PubMed ID: 16291710
    [Abstract] [Full Text] [Related]

  • 8. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
    Ramanathan S, Cheng A, Mittan A, Ebrahimi R, Kearney BP.
    J Clin Pharmacol; 2006 May; 46(5):559-66. PubMed ID: 16638739
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
    Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni M, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G.
    Antivir Ther; 2011 May; 16(4):499-504. PubMed ID: 21685537
    [Abstract] [Full Text] [Related]

  • 11. Low-dose ritonavir moderately enhances nelfinavir exposure.
    Kurowski M, Kaeser B, Sawyer A, Popescu M, Mrozikiewicz A.
    Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
    Kearney BP, Mathias A.
    Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard B, Pozniak A.
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.
    J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
    Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, Delaunay C, Chêne G, Brun-Vézinet F, Descamps D.
    Antivir Ther; 2004 Aug; 9(4):635-6. PubMed ID: 15456096
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.